Acronym:
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | All cancers | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Solid tumours |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Solid tumours |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
SGNLVA 005 open label phase 2 study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumours
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Chris Karapetis | Not Yet Recruiting |